Vaso-occlusive crisis

Nov 15, 2019

FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease

Mar 18, 2019

Arix Bioscience plc: Arix Co-leads $63 Million Series B Investment Round for Imara

Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Oct 09, 2018

Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

Jan 09, 2018

Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

Dec 13, 2017

Prolong Pharmaceuticals Announces Completion of Enrollment in Phase II Study of SANGUINATE® in the Treatment of Sickle Cell Disease Patients with Vaso-Occlusive Crisis in an Ambulatory Setting

Nov 08, 2017

Prolong Pharmaceuticals to Present New Research on SANGUINATE®, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease, at ASH Annual Meeting